EC
SMMT icon

Elmind Capital’s Summit Therapeutics SMMT Stock Holding History

Elmind Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.19M Buy
+493,820
New +$8.76M 1.81% 17

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Elmind Capital's SMMT Position: Q2 2026 in Review

Elmind Capital opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 493,820 shares worth $7.19M. The stake represents 1.81% of the portfolio and ranks #17 among its holdings.

242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Elmind Capital held 493,820 shares of Summit Therapeutics worth $7.19M as of Q2 2026.
  • Summit Therapeutics was a new Elmind Capital position in Q2 2026.
  • Summit Therapeutics made up 1.81% of Elmind Capital's portfolio in Q2 2026, its #17 holding.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.